VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.13, 2013-10, pp. : 1659-1667

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenetic aspects in treatment of colorectal cancer – an update

By Stoehlmacher Jan Goekkurt Eray Lenz Heinz-Josef

Pharmacogenomics, Vol. 4, Iss. 6, 2003-11 ,pp. : 767-777

Future Medicine

Access to resources Recommend Favorite

Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population

By Kjaer-Frifeldt Sanne Fredslund Rikke Lindebjerg Jan Hansen Torben Froestrup Spindler Karen-Lise Garm Jakobsen Anders

Pharmacogenomics, Vol. 13, Iss. 7, 2012-05 ,pp. : 763-770

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetic Polymorphisms in a Portuguese Gypsy Population

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 13, Iss. 1, 2015-12 ,pp. : 36-40

Bentham Science Publishers

Access to resources Recommend Favorite

Polymorphisms: prognostic factors in advanced NSCLC?

Inpharma, Vol. 1, Iss. 1454, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Molecular prognostic factors in patients with pancreatic cancer

By Tonini Giuseppe Pantano Francesco Vincenzi Bruno Gabbrielli Armando Coppola Roberto Santini Daniele

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 12, 2007-12 ,pp. : 1553-1569

Informa Healthcare

Access to resources Recommend Favorite